KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $163.1 million.

  • Biomarin Pharmaceutical's Other Non-Current Liabilities rose 2787.3% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 2787.3%. This contributed to the annual value of $128.8 million for FY2024, which is 741.15% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Other Non-Current Liabilities is $163.1 million, which was up 2787.3% from $148.8 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Other Non-Current Liabilities' 5-year high stood at $163.1 million during Q3 2025, with a 5-year trough of $92.4 million in Q1 2023.
  • For the 5-year period, Biomarin Pharmaceutical's Other Non-Current Liabilities averaged around $113.4 million, with its median value being $105.7 million (2021).
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Other Non-Current Liabilities tumbled by 1786.95% in 2021, and later surged by 2787.3% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Other Non-Current Liabilities stood at $98.4 million in 2021, then grew by 1.68% to $100.0 million in 2022, then rose by 19.92% to $119.9 million in 2023, then grew by 7.41% to $128.8 million in 2024, then grew by 26.57% to $163.1 million in 2025.
  • Its last three reported values are $163.1 million in Q3 2025, $148.8 million for Q2 2025, and $129.7 million during Q1 2025.